- Cellcolabs, a biotechnology startup based in Stockholm, has successfully secured €10.3 million in funding aimed at advancing the industrial-scale production of mesenchymal stem cells (MSCs). This investment was led by Titian Capital, with additional participation from other investors, signaling strong confidence in Cellcolabs’ innovative approach to stem cell manufacturing.
- The funding will be utilized to accelerate technical development and scale up production capabilities, allowing Cellcolabs to meet increasing global demand for stem cell therapies. The company’s technology is designed to significantly lower the cost of producing MSCs, with a target of achieving a 90% reduction compared to current market prices. This ambitious goal positions Cellcolabs as a potential game-changer in the stem cell industry.
- In a statement, Cellcolabs emphasized the importance of this funding round in its mission to democratize access to stem cell therapies worldwide. The startup plans to expand its reach into international markets, leveraging its scalable manufacturing processes to make these therapies more accessible to patients in need.
Source: Swedish Tech News
Leave feedback about this
You must be logged in to post a comment.